Author: GO2 for Lung Cancer Specialist, Science & Research, Brittney Nichols MPH, BSN-RN Each year, scientists and doctors from across the globe gather at IASLC’s World Conference on Lung Cancer (WCLC) to discuss the latest and greatest in lung [...]
Every year, lung cancer professionals from across the globe gather to connect and learn at the World Conference for Lung Cancer (WCLC). Members of the GO2 team just returned from WCLC 2023 hosted in Singapore, where they presented GO2’s [...]
The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring where oncologists and other physicians, researchers, industry members, and advocacy organizations like GO2 come together to share and learn the latest and most exciting news on [...]
By Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer New research on metastatic (stage 4) non-small cell lung cancer (NSCLC) was a hot topic at the 2023 American Society of Clinical Oncology (ASCO) meeting. Data from [...]
By Jennifer C. King, PhD, Chief Scientific Officer, GO2 for Lung Cancer While the past decade has seen the development of many new therapies for lung cancer, these drugs are typically first approved for metastatic cancer (cancer that has [...]
Question: "I’ve seen commercials for immunotherapy as a treatment for lung cancer. How does it work? How do I know if it’s a good treatment for me?" Answer: Immunotherapy is a type of cancer treatment that helps the body’s [...]
Authors: Renee Botello, MSc, Treatment and Trial Navigator; Daniel A. Saez, MSc, Manager of LungMATCH Navigation Program In 2022, the treatment landscape for lung cancer continued to evolve to provide breakthrough treatment options for people living with lung cancer. This [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program For many years, the treatment options given to patients diagnosed with early stage non-small cell lung cancer (NSCLC) was limited to surgery with or without chemotherapy to improve outcomes. However, [...]
What happens when your cancer becomes resistant to your course of treatment and progresses? That’s the question we explored in the September episode of our Lung Cancer Living Room series. Dr. David Gandara, professor emeritus and co-director of UC [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program Many patients with non-small cell lung cancer (NSCLC) rely on a class of treatments called immunotherapy to battle their cancer. The significant difference between immunotherapy and targeted therapy (the other [...]